Details

Autor(en) / Beteiligte

• Rinne, Juha O.
• Laihinen, Arto
• Någren, Kjell
• Ruottinen, Hanna
• Ruotsawnen, Ulla
• Rinne, Urpo K.

Titel

PET examination of the monoamine transporter with [11c]β-CIT and [11c]β-CFT in early parkinson's disease

Ist Teil von

• Synapse (New York, N.Y.), 1995-10, Vol.21 (2), p.97-103

Ort / Verlag

Hoboken: Wiley Subscription Services, Inc., A Wiley Company

Erscheinungsjahr

1995

Link zum Volltext

Quelle

Wiley Online Library Journals【Remote access available】

Beschreibungen/Notizen

• The monoamine transporter was studied in 4 healthy controls and 5 patients with early Parkinson's disease (PD), who had not received any antiparkinsonian medication, by means of positron emission tomography (PET) using two novel ligands, [11C]β‐CIT and [11C]β‐CFT. Both ligands showed highest uptake in the striatum. There was intermediate accumulation of activity in the thalamus and midbrain, which was more marked for [11C]β‐CIT than for [11C]β‐CFT. In the cortical areas, uptake of both ligands was not different from that seen in the cerebellum. In the controls, the putamen‐to‐cerebellum and caudate‐to‐cerebellum ratios for [11C]β‐CFT were higher than those for [11C]β‐CIT (putamen: 3.15± 0.39 for [11C]β‐CFT, and 1.84 ±0.10 for [11C]CIP‐CIT caudate: 3.15±0.31 for [llC]P‐CFT, and 1.95±0.17 for [11C]β‐CIT). Reduction from mean control value in PD patients was greater for [11C]β‐CFT (45% in the putamen contralateral to the predominant symptoms, P < 0.001) than for [11C]β‐CIT(20%, P > 0.05). [11C]β‐CFT uptake in the caudate nucleus was also diminished in PD patients (to 80% of the control mean, P < 0.05), whereas [11C]β‐CIT was within normal range (reduced to 90% of the control mean). These results indicate that both [11C]β‐CIT and [11C]β‐CFT are useful PET ligands to study brain monoamine transporter in healthy controls and in patients with PD. However, [11C]β‐CFT seems superior to [11C]β‐CIT in this respect. © 1995 Wiley‐Liss, Inc.